Post-infectious Autoimmune Cardiac Risk Index (Autoantibodies Panel)

Clinical calculation support · Verify results before clinical use

Autoantibody panel inputs

Enter each result on the same prespecified 0–5 normalized research scale.

—Index / 100
Use a normalized value from 0 to 5; this is not a laboratory-specific concentration or validated cutoff.Scale: 0–5
Use the same prespecified normalization method for every patient and assay.Scale: 0–5
Do not enter raw titers or assay units unless a validated conversion to the 0–5 research scale has been defined.Scale: 0–5
The source model does not define an assay method, unit, or validated normalization procedure.Scale: 0–5
Use a research-normalized value, not an unconverted raw laboratory result.Scale: 0–5
A harmonized assay and normalization protocol would be needed before comparing results across laboratories.Scale: 0–5
—Index / 100
Exploratory composite calculation

Enter all six values

The index is displayed only after all fields contain valid values from 0 to 5.

Important clinical limitationThis composite index has not been established as a validated diagnostic or prognostic instrument. No clinical risk categories, probability estimates, or treatment thresholds are assigned. Do not use this value alone to diagnose myocarditis/cardiomyopathy or initiate immunomodulatory treatment.

Method and interpretation

The original code specifies a weighted sum of six antibody inputs and converts the result to a 0–100 display. The arithmetic weights are retained for exploratory use only; they do not establish clinical validity.

MarkerWeight in original code
Anti-Myosin Antibody (AMA)25%
Anti-Troponin I Antibody (ATIA)20%
β1-Adrenergic Receptor Antibody20%
M2 Muscarinic Receptor Antibody15%
Cardiac Myosin Heavy Chain Antibody10%
Anti-Endothelial Cell Antibody (AECA)10%

Calculation retained from source code

Index = 20 × [0.25(AMA) + 0.20(ATIA) + 0.20(β1AR-Ab) + 0.15(M2R-Ab) + 0.10(MHC-Ab) + 0.10(AECA)], assuming every input has first been normalized to a 0–5 scale. Under that assumption, the mathematical output ranges from 0 to 100.

What the value means

  • A higher result means only that the entered normalized values produce a higher weighted arithmetic index.
  • It is not a validated probability of autoimmune cardiac disease, myocarditis, or dilated cardiomyopathy.
  • The input scale, coefficients, and 0–100 transformation are not clinically validated by the cited references.
  • No low/moderate/high/very-high category is shown because the original cutoffs lack a verified derivation study.

Clinical context and limitations

Cardiac autoantibodies have been investigated in selected immune-mediated cardiac conditions, but findings depend on the antibody, assay method, population, and clinical context. Evidence about individual autoantibodies does not validate this six-marker composite.

Clinical assessment

When myocarditis or an inflammatory myocardial syndrome is suspected, evaluation should follow established diagnostic pathways and the clinical presentation. Depending on the case, this may include ECG, cardiac biomarkers, echocardiography, cardiac magnetic resonance, and selected endomyocardial biopsy or other investigations.

Before research use

  • Define each assay, units, reference range, and normalization method in advance.
  • Provide a derivation dataset and justify each coefficient statistically and biologically.
  • Evaluate discrimination, calibration, external validation, and clinical utility before proposing cutoffs.
  • Do not use this exploratory index to direct diagnosis or treatment.

References

Schulz-Menger J, Collini V, Gröschel J, et al.; ESC Scientific Document Group.2025 ESC Guidelines for the management of myocarditis and pericarditis. European Heart Journal. 2025;46(40):3952–4041. DOI: 10.1093/eurheartj/ehaf192. Used for the clinical-context section; it does not validate this composite index.
Caforio ALP, Pankuweit S, Arbustini E, et al.Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal. 2013;34(33):2636–2648. DOI: 10.1093/eurheartj/eht210; PMID: 23824828. General myocarditis position statement; it does not validate this six-marker score or its coefficients.
Clinical disclaimer: This is an educational/research calculator, not a validated clinical decision rule. Its output is a mathematical index based on user-entered normalized values. It must not replace clinical assessment, guideline-based investigation, or specialist judgement. No patient data are submitted by this page; calculations run locally in the browser.